Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Borah Spoorenberg"'
Autor:
Cong Liu, Milena Schönke, Borah Spoorenberg, Joost M Lambooij, Hendrik JP van der Zande, Enchen Zhou, Maarten E Tushuizen, Anne-Christine Andreasson, Andrew Park, Stephanie Oldham, Martin Uhrbom, Ingela Ahlstedt, Yasuhiro Ikeda, Kristina Wallenius, Xiao-Rong Peng, Bruno Guigas, Mariëtte R Boon, Yanan Wang, Patrick CN Rensen
Publikováno v:
eLife, Vol 12 (2023)
Analogues of the hepatokine fibroblast growth factor 21 (FGF21) are in clinical development for type 2 diabetes and nonalcoholic steatohepatitis (NASH) treatment. Although their glucose-lowering and insulin-sensitizing effects have been largely unrav
Externí odkaz:
https://doaj.org/article/10b3762987d94deeac6dedce6336b7ac
Autor:
Cong Liu, Milena Schönke, Borah Spoorenberg, Joost M Lambooij, Hendrik JP van der Zande, Enchen Zhou, Maarten E Tushuizen, Anne-Christine Andreasson, Andrew Park, Stephanie Oldham, Martin Uhrbom, Ingela Ahlstedt, Yasuhiro Ikeda, Kristina Wallenius, Xiao-Rong Peng, Bruno Guigas, Mariëtte R Boon, Yanan Wang, Patrick CN Rensen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b99d425453df9a925aa60e01e5fc280
https://doi.org/10.7554/elife.83075.sa2
https://doi.org/10.7554/elife.83075.sa2
Autor:
Cong Liu, Milena Schönke, Borah Spoorenberg, Joost M Lambooij, Hendrik JP van der Zande, Enchen Zhou, Maarten E Tushuizen, Anne-Christine Andreasson, Andrew Park, Stephanie Oldham, Martin Uhrbom, Ingela Ahlstedt, Yasuhiro Ikeda, Kristina Wallenius, Xiao-Rong Peng, Bruno Guigas, Mariëtte R Boon, Yanan Wang, Patrick CN Rensen
Analogues of the hepatokine FGF21 are in clinical development for type 2 diabetes and nonalcoholic steatohepatitis (NASH) treatment. Although their glucose-lowering and insulin-sensitizing effects have been largely unraveled, the mechanisms by which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65e6766169da40861a1df700705827a6
https://doi.org/10.1101/2022.09.20.508654
https://doi.org/10.1101/2022.09.20.508654